MetaCap

Summit Therapeutics (SMMT) vs TG Therapeutics (TGTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

TG Therapeutics (TGTX) has outperformed Summit Therapeutics (SMMT) over the past year, gaining 98.2% versus a loss of 38.5%. Over five years, TGTX leads with a +164.1% price change compared with +92.8% for SMMT. TG Therapeutics is the larger company by market cap ($9.57 billion vs $7.96 billion), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SMMT-38.54%TGTX+98.25%
+114%+34%-46%
Nov 21, 20251 yearNov 20, 2026
SMMT+85.98%TGTX+159.48%
+526%+206%-115%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SMMT versus TGTX key metrics
MetricSMMTTGTX
Share price$9.95$63.34
Market cap$7.96B$9.57B
1-day change-5.87%-2.37%
YTD return-43.11%+112.48%
1-year return-38.54%+98.25%
5-year return+92.83%+164.14%
P/E ratio (TTM)—94.54
Forward P/E—24.81
EPS (TTM)$-1.06$0.67
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$616.29M
Revenue growth (YoY)—+87.32%
Net income (latest FY)$-1.08B$447.18M
Gross margin—83.66%
Operating margin—20.01%
Net margin—72.56%
52-week high$29.23$68.03
52-week low$9.89$26.76
Distance from 52-week high-65.96%-6.89%
Analyst consensusbuystrong_buy
Avg. price target upside+189.15%+9.61%
Average volume6.68M1.86M
Shares outstanding799.76M151.15M
Employees265399
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TGTX has outperformed SMMT by 136.8 percentage points over the past year.

About Summit Therapeutics

SMMT stock →

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).

Health Care · Biotechnology: Pharmaceutical Preparations · 265 employees

About TG Therapeutics

TGTX stock →

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Health Care · Biotechnology: Pharmaceutical Preparations · 399 employees

SMMT vs TGTX FAQ

Which is bigger, Summit Therapeutics or TG Therapeutics?

TG Therapeutics (TGTX) is larger, with a market capitalization of $9.57B compared with $7.96B for Summit Therapeutics (SMMT).

Which stock has performed better over the past year, SMMT or TGTX?

TGTX returned +98.25% over the past 12 months, compared with -38.54% for SMMT (price return, excluding dividends). Past performance does not predict future results.

Are Summit Therapeutics and TG Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons